BE741948A - N-carbonyl imidazolines - Google Patents

N-carbonyl imidazolines

Info

Publication number
BE741948A
BE741948A BE741948DA BE741948A BE 741948 A BE741948 A BE 741948A BE 741948D A BE741948D A BE 741948DA BE 741948 A BE741948 A BE 741948A
Authority
BE
Belgium
Prior art keywords
desc
page number
clms page
aryl
alkyl
Prior art date
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE741948A publication Critical patent/BE741948A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/50Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

HYPOTENSIVE HYDROGLYCEAMIC N-CARBAMOYL-ARYLAMINOIMIDAZOLINES. M3A. Are new cmpds. of formula (I) (where R1 R2 and R3 are H, halogen (pref. Cl or Br), alkyl, alkoxy, CF3 or CN; R4 is alkyl, cycoalkyl, aryl opt. substd. by halogen or alkyl, aralkyl opt. substd. R5 is H or aryl; X is O or S) and may be made by reacting a correspg. imidazoline deriv. with a carbamoyl chloride or isocyanate. The cmpds. may be converted into their acid addition salts in known manner. Prefd. cpds. have R1, R2, R3 = 2,6- dichloro; X = O; R5 = H and R4 = 1-4C alkyl or substd. phenyl.

Description

  

   <Desc/Clms Page number 1> 
 
 EMI1.1 
 



  X-carbaaol1-illida.zol:2,nes et procéà& pour les préparer. 



     @   La présente invention concerne de nouvelles 2-arylamiro-lmidazolines substituées contenant un radical   carbamoyle   et répondant à la foriule   générale: -   
 EMI1.2 
 de s'ne que leurs sols d'addition d'acides. Dans la   formule   ci-   ' @   

 <Desc/Clms Page number 2> 

 dessus, R1, R2 et R3 identiques ou différents représentent des atones d'hydrogène ou d'halogène ou des radicaux trifluerosethyle   cya-nc,alkyle   ou alkoxy et R4 représente un radical alkyle en   traire   droite ou ramifiée ou   cycloalkyle   ou bien aryle ou aralkyle portant   éventuellement corsée   substituantsun ou plu- sieurs atones d'halogène   cu   radicaux   alkyle,

     R5 représente un atome d'hydrogène ou un radical aryle éventuellement substitué et X représente un   atoe   d'oxygène ou de   soufre.   



   Or. prépare les composes de formule I a) en faisant réagir une arylamino-imidazoline substi- tuée de formule générale 
 EMI2.1 
 où R1, R et R3 ont les significations qui leur ont été données   ci-dessus' avec   un chlorure de   carbamoyle   de formule-. 
 EMI2.2 
 où   R   et   R   ont les significations qui leur ont été données ci-dessus,ou bien ¯¯¯¯¯ b) en faisant réagir une arylamino-imidazolne substi- tuée de formule II avec un isocyanate de   formule:   
 EMI2.3 
 où   R   a la signification qui lui a été donnée ci-dessus, étant entendu que dans le cas b) on obtient des composés où   R   représen- te un atone d'hydrogène. 



   On exécute les deux procédés de préférence dans des solvants inertes, comme le benzène ou le   chloroforme.   On les 

 <Desc/Clms Page number 3> 

 
 EMI3.1 
 exécute pr1!".'-'5p'11e:::;e:'1t à la te-.-, --er:.4Ure é.'Í"1ante. Les condi- tiens de réacica prlci=es à4penie#t e la réactivité des réac- tifs MIS en jeu. 



  Les -cartao,I-iaidax:.Iâr.-2 faisant l'objet de l'inventicn et repensant à la !'or""7Ule générale 1 peuvent être trsasforseesce la sanire habituelle n leurs sels d'adjiticn d'acides phjsi(lo±lquect accert#11=s. Des acides ccnvenant pour la fcmaticn des sels sont,rr exe=-,ile,1 $acide chlor:uydri- que, l'acide brc=hydrique, l'aci3 1;

  lhyàriqué, l'acide sulfUri- que, l'acide phospherique, l'acide   nitrique,   l'acide acétique, l'acide   propionique,     l'acide     butyrique,   l'acide valérianique,   l'acide   oxalique, l'acide malonique, l'acide succinique, l'acide   maléique,   l'acide fumarique, l'acide tactique, l'acide tartrique, l'acide citrique, l'acide malique,   l'acide   benzoïque,   l'acide     phtalique,l'acide   cinnamique, l'acide salicylique, l'acide as- 
 EMI3.2 
 corbique, la 3-ci-.lcrctao-hiï7.ine et ainsi de suite. 



   Les composés de formuel générale 1 faisant l'objet de   l'invention   de même que leurs   sels   d'addition d'acides se distinguent par des propriétés thérapeutiques intéressantes. 



   Ils ont principalement un effet d'abaissement de la tension ar- térielle et du taux de sucre sanguin et peuvent par conséquent trouver leur application dans le traitement des diverses mani-   festations   de l'hypertonie et du diabète. 



   Les composés de formule générale 1 de même que leurs sels d'addition d'acides peuvent être administrés par voie ora- le,entérale ou parentérale La dose en administration orale est de 0,5 à 100 et de préférence de 3 à 30 mg. Les composés de formule 1 ainsi que leurs sels d'addition d'acides peuvent être administrés aussi en   môme     temrs   que d'autres agents ayant pour effet d'abaisser la tension artérielle ou le teux de sucre 

 <Desc/Clms Page number 4> 

 
 EMI4.1 
 sanguin, par CXC2nl. des bcn:cth1Qd1n:1nc tt que d'autres agents aours, Par exp.nle des spas-olytiq,in3e des tlhUdlu:6ttque., d8 diurétiques ou des analgésiques.

   Des co.,t.od tions taléniques apprc7riée  sent rkr .xe10 les cor1, capsules, suppo- tîtotres, solution. ou foudre pour la desquels on peut utIHj* los *d4i:lfs {:tl<Jt'.f tels que les adju-;ant., Vv!tt!<.ajE nts d.i ùfs=gr*'q.àiJ; O'J lubrl(hnts de c*::o çue lei rjb&tncas pcj'tt-.r.t .i i.;,,r<>;r ,.u:\t ;&ct10:\ przlontze. La de ces et'::;''' ! --.s est *x+çuti* do 1& habituelle $';1" . 1 : !"{!c.:.l.j,3 c/;'zmtJt. 



  Lz ..x<.-"ls suiva;ts 1.'* i; b':.?. ntion 31r.!. la liwstor  ce""lt ' -- l--?h\r--h-'-ty:cr;'.'?-? à;if8 ?fi? (a--(2¯), );c¯ifr; 1->;r.. C,n dix:ut %,5 g (9,C2 ;zle) do 2-(2,6-fichlarc- dans un =X;ar;;<> do 25 --il de chlore.- tom* et d* 2µ 1 de Eenz"n* ab>-ili #; t 2 t t :>1#- tion scutt<e à acuité en 10 a1mttes et. :':.s a61t3tçn à la twTpë- :rature easîanK 407 g d'14oc1.nt. de 2#6-d1chloroph nrl.. Apr.. pluffieur3 heures d'±ltlon cette on  é>aro It préc1plti par filtration sous vide, puis on lu lave solsneusesent au eMM-cforse et on le sttch..

   On obtie.-It ainsi en u;mt.1 tô de 6,3 tp ce qul corrt3pond à 75eO de la çuontit4 tw-orlque, un* s':.1b:t::t1C4! qui apparalt pure à la en --Ouche mi;ce et à l'analyse élé=*;tniro *t qui fond à z66-266C* On peut s1'nt..'t1;nr par le procéd' de I*e=emple 1 les sutstances figurant au tableau ci-après: . 

 <Desc/Clms Page number 5> 

 
 EMI5.1 
 
 EMI5.2 
 



  Exem- BL R E3 X Ry R5 P. F. 1 oc 2 2-Cl 6.CI H z3 . 3' 'ri P-01-202 Cl drate) 3 3-Cl H 0 X 207 "2"5 Ù 13-1 x-- '%¯ (chlorhy- drate) 2-CH, 6-c2F.5 B 0 " iâ 16?-19t Cl 6 4-CH 3 E o tj- a 219 4-OEI3 H '9 il la-6-193 dra*,e) 4-Cî!,3 H H "3?7 3 188 """"  W*(3îilµi (chlorhy- drate) 10 2-Cl 6-Cl H 0 n-CiH7 E dol (nitrate) 11 2-CI 6-CI E 0 O- S 199-201 M 2-CI 6-Ci H 0 3Ù 219-220 ,Cl 13 2-Cl 6-Cl E 0 O- il 230-23l ci 2-CI 6-Ci H tu 2:7-219 

 <Desc/Clms Page number 6> 

 
 EMI6.1 
 Exea- R2 R. 1-14 a P.

   F. 9 OC e ...'¯¯¯L####¯¯¯¯¯¯¯ 15 2-Cl 6-ci H 0 ci- li 235-236 16 2-Cl 6-Cl H S O- H 180/30S #!' (chlorhy- drate) 17 2-Ci .-cH3 H 0 CI- n 158-159 18 4-F H 0 ci- H 197-199 1 4-C=N H 0 G- e , - 222-225 20 2-CF- H H 0 ci- H 1884 EXEMPLE A: Dragées 
 EMI6.2 
 
<tb> (a)Composition
<tb> 
<tb> chlorhydrate <SEP> de <SEP> 1-(2,6-dichlorophényl-
<tb> 
 
 EMI6.3 
 c&rbanoyl)-2-(26-dichloro?henylac!ino)- 
 EMI6.4 
 
<tb> imidazoline- <SEP> (2)- <SEP> 15mg
<tb> 
<tb> :

  Lactose <SEP> 60 <SEP> mg
<tb> 
<tb> ¯¯¯¯ <SEP> amidon <SEP> de <SEP> nais <SEP> 125' <SEP> mg
<tb> 
<tb> phosphate <SEP> de <SEP> calcium <SEP> secondaire <SEP> 40 <SEP> mg
<tb> 
<tb> amidon <SEP> soluble <SEP> 3 <SEP> mg
<tb> 
<tb> stéarate <SEP> de <SEP> magnésium <SEP> 3 <SEP> mg
<tb> 
<tb> acide <SEP> silicique <SEP> colloïdal <SEP> 4 <SEP> mg
<tb> 
<tb> Total <SEP> 250 <SEP> mg
<tb> 
 (b) Mode opératoire 
On   mélange     l'agent   actif avec une fraction des adju=   Tant.,   puis on malaxe le mélange résultant   vivenent   avec une solution aqueuse de l'amidon soluble et on granule le produit 

 <Desc/Clms Page number 7> 

 
 EMI7.1 
 )mur-" ' , 1;.,"'t "fi-:; " ,. '"';'"J;t. ") a . Y3 .. .. 



  Ultant 4*la manière habituelle à l'aide d'un ta.mis. On ",",,' .( ,,;:... ,,;: ...F ..,..., l;i"f" ..,"" ....<; ....T¯.... -,..... ,,; ""II). e l.ss-,raaz3es avec le reste des" adjuvants et on press ,[, - "1 noyaux' ' de dragées <Pun poids de 251 mg qu'on< ' nsuilt';i manière , ,i ' n > -s u"i 'o;en" 'sucr;'c, J:;;':, ,à ,¯ ¯ ¯- , . ¯ la madère habitiie3.lé aa moyeri de 'sue 2'¯ .. arabique';.:; . '" . '. t"\'1.:.t':,'- ..-;;,o,,,1tf et;}..''-   '::';"-'<;:!> , :., "' / " ,   " ¯ '"îJ'.:p''\-' LE ni es .. "--f,"I?O ':l'f"..F'..o;' /1( .rr..;...""";:- 1 . --'...';','..."'"   .. .Ji...'t '1.. ,...""'J."'" r...-'t.11 Colti ' . '.;.:"'"'" eYÂ< '.l"-",;'l,',,;"""' z<' !':''/'; AÎ Cp!3mo, ..;: \!i,,--,,':'7 - .;: ² -:"'.'  " '" ';;:;'":;'.1\:' : .. iod1:q'drate de 1-(isopropylcarbamoyl)- / .¯ ' '   'i ' "± . -1. 



  ^ 2-aLoro-"-dthyïphény3amino-3,mi- , , .. ". 7 ">f' . ':-; ..-r daS0l1ne-(2) m:¯;'' . - 1,; mg .,;: (,(.' ")< ch1qe de sodiUl:1' fFi,V 17 J 0 mg , , chlprure de sodiua 1730 mg Eauttistil1ée pour faire 2,0 ml .'"' J , (b) Mode" opératoire ..' ", On dissout l'agent actif et le chlorure de sodium de l'eau et on introduit la solution en atmosphère d'azote ..."lj des ampoules de verre. ".,'< '1 -' J'ii '!.,.. jf z-s ±ÉiÀ%il *N.R. riz au , bzz¯ ¯ - - . - - ¯...-.....;.:-t,":-.<o-........ ¯:. -;..-- .... :;.t1.:...-.:::-..- , ¯ .,- ,;¯, . ,x - ,¯" ... : - . 



  'j.j; R E V E ïr D 1 C A T 1 0 N S. , z. - N-Carbamoyl-acylawino-imidazolines -(2) de formule 4"'.. " 

**ATTENTION** fin du champ DESC peut contenir debut de CLMS **.



   <Desc / Clms Page number 1>
 
 EMI1.1
 



  X-carbaaol1-illida.zol: 2, nes and procéà & to prepare them.



     @ The present invention relates to novel substituted 2-arylamiro-lmidazolines containing a carbamoyl radical and corresponding to the general formula: -
 EMI1.2
 of s'ne that their soils of addition of acids. In the formula below- '@

 <Desc / Clms Page number 2>

 above, R1, R2 and R3 which are identical or different represent hydrogen or halogen atoms or trifluerosethyl cya-nc, alkyl or alkoxy radicals and R4 represents a straight or branched alkyl or cycloalkyl or aryl or aralkyl radical bearing optionally full-bodied substituting one or more halogen atoms or alkyl radicals,

     R5 represents a hydrogen atom or an optionally substituted aryl radical and X represents an oxygen or sulfur atom.



   Or. Prepares the compounds of formula I a) by reacting a substituted arylaminoimidazoline of general formula
 EMI2.1
 where R1, R and R3 have the meanings given to them above 'with a carbamoyl chloride of formula-.
 EMI2.2
 where R and R have the meanings given to them above, or ¯¯¯¯¯ b) by reacting a substituted arylaminoimidazole of formula II with an isocyanate of formula:
 EMI2.3
 where R has the meaning given to it above, it being understood that in case b) compounds are obtained where R represents a hydrogen atom.



   Both processes are preferably carried out in inert solvents, such as benzene or chloroform. Is the

 <Desc / Clms Page number 3>

 
 EMI3.1
 execute pr1! ".'- '5p'11e :::; e:' 1t at te -.-, --er: .4Ure é.'Í" 1ante. The reactive conditions prlci = es to 4penie # t the reactivity of the reagents put into play.



  The -cartao, I-iaidax: .Iâr.-2 being the subject of the inventicn and rethinking the! 'Or "" 7Ule general 1 can be trsasforseesce the usual sanire n their salts of addition of phjsi ( lo ± lquect accert # 11 = s. Acids suitable for the fcmaticn of salts are, rr exe = -, ile, 1 $ chlor: uidric acid, brc acid = hydric, aci3 1;

  hydric acid, sulfuric acid, phospheric acid, nitric acid, acetic acid, propionic acid, butyric acid, valerianic acid, oxalic acid, malonic acid, l succinic acid, maleic acid, fumaric acid, tactic acid, tartaric acid, citric acid, malic acid, benzoic acid, phthalic acid, cinnamic acid, l 'salicylic acid, as-
 EMI3.2
 corbique, 3-ci-.lcrctao-hiï7.ine and so on.



   The compounds of general form 1 forming the subject of the invention, as well as their acid addition salts, are distinguished by interesting therapeutic properties.



   They mainly have a lowering effect on blood pressure and blood sugar level and can therefore find application in the treatment of various manifestations of hypertonia and diabetes.



   The compounds of general formula 1 as well as their acid addition salts can be administered orally, enterally or parenterally. The dose for oral administration is from 0.5 to 100 and preferably from 3 to 30 mg. The compounds of formula 1 as well as their acid addition salts can also be administered together with other agents having the effect of lowering blood pressure or sugar levels.

 <Desc / Clms Page number 4>

 
 EMI4.1
 blood, by CXC2nl. bcn: cth1Qd1n: 1nc tt as other agents aours, For example spas-olytiq, in3e tlhUdlu: 6ttque., d8 diuretics or analgesics.

   Appreciated talenic co., Od tions smell rkr .xe10 the cor1, capsules, suppositories, solution. or lightning for which one can useIHj * los * d4i: lfs {: tl <Jt'.f such as adju-; ant., Vv! tt! <. adjE nts d.i ùfs = gr * 'q.àiJ; O'J lubrl (hnts de c * :: o çue lei rjb & tncas pcj'tt-.rt .i i.; ,, r <>; r, .u: \ t; & ct10: \ przlontze. The of these and ' ::; '' '! -. s is * x + çuti * do 1 & usual $'; 1 ". 1:!" {! c.:.lj,3 c /; 'zmtJt.



  Lz ..x <.- "ls followed; ts 1. '* I; b':.?. Ntion 31r.!. La liwstor ce" "lt '- l -? H \ r - h-' -ty: cr; '.'? -? to; if8? fi? (a - (2¯),); c¯ifr; 1 ->; r .. C, n ten: ut%, 5 g ( 9, C2; zle) do 2- (2,6-Fichlarc- in un = X; ar ;; <> do 25 --il of chlorine.- tom * and d * 2µ 1 of Eenz "n * ab> - ili #; t 2 tt:> 1 # - acuity scutt <e tion in 10 a1mttes and.: ':. s a61t3tçn at the twTpë-: easîanK rature 407 g of 14oc1.nt. of 2 # 6-d1chloroph nrl .. After .. several 3 hours of ± ltlon this was> aro It preclplti by vacuum filtration, then it was washed thoroughly with eMM-cforse and sttch ..

   We thus obtain.-It in u; mt.1 tô of 6.3 tp which corresponds to 75eO of the tw-orlc çuontit4, a * s':. 1b: t :: t1C4! which appears pure to the en --Ouche mi; ce and to the analysis élé = *; tniro * t which melts at z66-266C * We can s1'nt .. 't1; nr by the procedure of I * e = Example 1 the substances shown in the table below:.

 <Desc / Clms Page number 5>

 
 EMI5.1
 
 EMI5.2
 



  Exem- BL R E3 X Ry R5 P. F. 1 oc 2 2-Cl 6.CI H z3. 3 '' ri P-01-202 Cl drate) 3 3-Cl H 0 X 207 "2" 5 Ù 13-1 x-- '% ¯ (hydrochloride) 2-CH, 6-c2F.5 B 0 "iâ 16? -19t Cl 6 4-CH 3 E o tj- a 219 4-OEI3 H '9 il la-6-193 dra *, e) 4-Cî!, 3 HH" 3? 7 3 188 "" "" W * (3îilµi (hydrochloride) 10 2-Cl 6-Cl H 0 n-CiH7 E dol (nitrate) 11 2-CI 6-CI E 0 O- S 199-201 M 2-CI 6-Ci H 0 3Ù 219-220, Cl 13 2-Cl 6-Cl E 0 O- il 230-23l ci 2-CI 6-Ci H tu 2: 7-219

 <Desc / Clms Page number 6>

 
 EMI6.1
 Exea- R2 R. 1-14 a P.

   F. 9 OC e ... '¯¯¯L #### ¯¯¯¯¯¯¯15 2-Cl 6-ci H 0 ci- li 235-236 16 2-Cl 6-Cl HS O- H 180 / 30S #! ' (hydrochloride) 17 2-Ci.-cH3 H 0 CI- n 158-159 18 4-FH 0 ci- H 197-199 1 4-C = NH 0 G- e, - 222-225 20 2-CF - HH 0 ci- H 1884 EXAMPLE A: Dragees
 EMI6.2
 
<tb> (a) Composition
<tb>
<tb> <SEP> 1- (2,6-dichlorophenyl-
<tb>
 
 EMI6.3
 c & rbanoyl) -2- (26-dichloro? henylac! ino) -
 EMI6.4
 
<tb> imidazoline- <SEP> (2) - <SEP> 15mg
<tb>
<tb>:

  Lactose <SEP> 60 <SEP> mg
<tb>
<tb> ¯¯¯¯ <SEP> starch <SEP> from <SEP> but <SEP> 125 '<SEP> mg
<tb>
<tb> <SEP> calcium <SEP> secondary <SEP> phosphate <SEP> 40 <SEP> mg
<tb>
<tb> starch <SEP> soluble <SEP> 3 <SEP> mg
<tb>
<tb> magnesium <SEP> stearate <SEP> <SEP> 3 <SEP> mg
<tb>
<tb> <SEP> silicic acid <SEP> colloidal <SEP> 4 <SEP> mg
<tb>
<tb> Total <SEP> 250 <SEP> mg
<tb>
 (b) Procedure
The active agent is mixed with a fraction of the adju = Tant., Then the resulting mixture is kneaded alive with an aqueous solution of the soluble starch and the product is granulated.

 <Desc / Clms Page number 7>

 
 EMI7.1
 ) wall- "', 1;.,"' t "fi- :;",. '"'; '" J; t. ") a. Y3 .. ..



  Ultant 4 * the usual way using a ta.mis. On "," ,, '. (,,;: ... ,,;: ... F .., ..., l; i "f" .., "" .... <; .. ..T¯ .... -, ..... ,,; "" II). e l.ss-, raaz3es with the rest of the "adjuvants and one press, [, -" 1 cores' 'of dragees <Pun weight of 251 mg that <' nsuilt '; i way,, i' n> - su "i 'o; en"' sucr; 'c, J: ;;' :, to, ¯ ¯ ¯-,. ¯ madeira habitiie3.lé aa moyeri of 'sue 2' ¯ .. arabic ';.:; . '".'. t" \ '1.:.t':,'- ..- ;;, o ,,, 1tf and;} ..''-' :: '; "-' <;:! >,:., "'/", "¯'" îJ '.: P' '\ -' LE ni es .. "--f," I? O ': l'f ".. F' .. o; ' / 1 (.rr ..; ... "" ";: - 1. --'... ';', '..."' ".. .Ji ... 't' 1 .., ... "" 'J. "'" R ...- 't.11 Colti'. '.;.: "'" '"EYÂ <' .l" - ",; 'l,' ,,; "" "'z <'! ':' '/'; AÎ Cp! 3mo, ..;: \! i ,, - ,, ':' 7 -.;: ² -:" '.' "' "';;:;'" :; '. 1 \:': .. iod1: 1- (isopropylcarbamoyl) q'drate - / .¯ '' 'i' "±. -1.



  ^ 2-aLoro - "- dthyïphény3amino-3, mi-,, ..". 7 "> f '.': -; ..- r daS0l1ne- (2) m: ¯; ''. - 1 ,; mg.,;: (, (. '") <Ch1qe of sodiUl: 1' fFi , V 17 J 0 mg,, sodium chloride 1730 mg Auttistilée to make 2.0 ml. '"' J, (b) Procedure" "The active agent and sodium chloride are dissolved in the mixture. 'water and the solution is introduced in a nitrogen atmosphere ... "lj glass ampoules.".,' <'1 -' J'ii '!., .. jf zs ± ÉiÀ% il * NR rice au , bzz¯ ¯ - -. - - ¯ ...-.....;.: - t, ": -. <o -........ ¯ :. -; ..--. ...:;. t1.:...-.:::-..-, ¯., -,; ¯,., x -, ¯ "...: -.



  'not a word; R E V E ïr D 1 C A T 1 0 N S., z. - N-Carbamoyl-acylawino-imidazolines - (2) of formula 4 "'.."

** ATTENTION ** end of DESC field can contain start of CLMS **.

 

Claims (1)

EMI7.2 kdnéral til-til ' ' . " Ni eS n-.ï (tF'F-t 113 V " i1 ' ..y EMI7.3 pi ¯¯ R, 2 et R3 identiques ou différents représentent des aomes d'h7drogène ou d'nalogène, lesquels sont de préférence des atomes de chlore ou de brome; ou des radicaux alkyle, alkoX7, - bJr1t1uoro -thyle , ou cyano, R représente un radical alkyle en une droite ou ramifiées oycloa.lkyle, aryle portant éventuel-' 'ï1 lèsent comme substituantsun ou plusieurs atomes d'halogène nu ; 1caux le,ou aralkyle eventuellenent substitué , R Jreg¯ Ô-: 4 '..f¯- . '1' <Desc/Clms Page number 8> EMI8.1 soin'.* un atc--* 4,fh.rtW ou un n"' '7.::. et X re:-:';,se.cte un ato> doxygèffl ou de toa.f, dt q:4-e lettre sels 4-add1- t:f.#:1 4*<Md<. EMI7.2 kdnéral til-til ''. "Ni eS n-.ï (tF'F-t 113 V" i1 '..y EMI7.3 identical or different pi ¯¯ R, 2 and R3 represent hydrogen or halogen atoms, which are preferably chlorine or bromine atoms; or alkyl, alkoX7, - bJr1t1uoro -thyle, or cyano radicals, R represents an alkyl radical in a straight line or branched oycloa.lkyle, aryl carrying optionally - '' ï1 damage as substituentsone or more atoms of naked halogen; 1caux le, or optionally substituted aralkyl, R Jreg¯ Ô-: 4 '..f¯-. '1' <Desc / Clms Page number 8> EMI8.1 care '. * un atc - * 4, fh.rtW or n "' '7. ::. and X re: -:' ;, se.cte an ato> doxygèffl or from toa.f, dt q: 4-e letter salts 4-add1- t: f. #: 1 4 * <Md <. 2' - la +v *asìeiùô.x 1 , de òm±> gé- nî"2 EMI8.2 EMI8.3 et *t j r.;-riJet1t4Ct 41.. aoenos p.a:,"'o qui aon: de pMf'ronc* <M#:<'< 4. ehlsr* s â ?, $(.:;;.t'1c..t.1o:L <r.t1 lu1 a 4t4 dwx<* ci-4es.w.,4. ne-:. q#1 1 >rà .se:.. d*addition 4'*#14e* .rs1oh>t1quoc .tt .cr,aha,. 2 '- la + v * asìeiùô.x 1, from òm ±> genî "2 EMI8.2 EMI8.3 and * tj r.; - riJet1t4Ct 41 .. aoenos pa:, "'o qui aon: de pMf'ronc * <M #: <' <4. ehlsr * s â?, $ (.: ;;. t ' 1c..t.1o: L <r.t1 lu1 a 4t4 dwx <* ci-4es.w., 4. Ne- :. q # 1 1> rà .se: .. d * addition 4 '* # 14th * .rs1oh> t1quoc .tt .cr, aha ,. 3 - 0t?'os< 'Mmt 1-: rnj1ca1cns 1 .t/ou 2 4< iermao géaér>1*d EMI8.4 EMI8.5 c4 :a,. nr1'l.1mU UA l'a41ca1 alk.11. tuent cenp. tut hoen'À % at060. d* <e<fbes< OU un radical rbiD.1le portant 11t. eM< ])Mt<M.t<4< <ta%<m 4#h lotm cou n41- cac n4thy1*, 4* n%a* t 1 .:.:'...1. 4"-.ci1t.lo13- 4'&c14e#;o 4 - ?Mc16' 4* prhant10n 4* C''c))!trb'?y--yy.ïMdja&- 1 S4*aoii+a-ce> <* tonw.1. ,4Mra1e. EMI8.6 <Desc/Clms Page number 9> EMI9.1 oh %, B.2 et R) :ep"és@:1t.et:t; des a.rc., d7byèrol'Óne ou dJt1:.alcg;n<ff ., iJ radicaux al3zrlee a.J.1:oJ:;7, t-rir>rro=6Uy=le ou cyami se:1te un 1cal xltyle es CU± droite CQ rasifie-e) C)"Ci0.aI.t71e, ar:;le T'crtaat wet:ael:e::ent =--me sabstitaants ou ;:1usle".l1":!: 3 - 0t? 'Os <' Mmt 1-: rnj1ca1cns 1 .t / or 2 4 <iermao géaér> 1 * d EMI8.4 EMI8.5 c4: a ,. nr1'l.1mU UA a41ca1 alk.11. kill cenp. tut hoen'A% at060. d * <e <fbes <OR an rbiD.1le radical carrying 11t. eM <]) Mt <M.t <4 <<ta% <m 4 # h lotm cou n41- cac n4thy1 *, 4 * n% a * t 1.:.: '... 1. 4 "-. Ci1t.lo13- 4 '& c14e #; o 4 -? Mc16' 4 * prhant10n 4 * C''c))! Trb '? Y - yy.ïMdja & - 1 S4 * aoii + a-ce> <* tonw.1., 4Mra1e. EMI8.6 <Desc / Clms Page number 9> EMI9.1 oh%, B.2 and R): ep "és @: 1t.et: t; des a.rc., d7byèrol'Óne or dJt1: .alcg; n <ff., iJ radicals al3zrlee aJ1: oJ :; 7, t-rir> rro = 6Uy = le or cyami se: 1te un 1cal xltyle es CU ± straight CQ rasifi-e) C) "Ci0.aI.t71e, ar:; le T'crtaat wet: ael: e: : ent = - me sabstitaants or;: 1usle ".l1":!: atzres d.'ha1c,tn ou :-z:.:i1::aa a11:y2 ou az>bgLe G14/.,'S4.pw6wnA l.Ai nl3:wbW wY, 61.w..njYT irA.ly 3."'"-,- d2hyd=gl-ne s 1eA un ra:!1 c:1l aryle et X # A r Lsa 1 V xi . t:.::.e d' oY..::":ène en de $Carre. carcti:is6 en ce qc: a) en fait réncir wne K." (iasi i: r.w srs'¯.s.iSywâ.ivwdVr6r aubat1tu.. de t3. ,.ralt: EMI9.2 EMI9.3 oà 1i , R et. 11) ont les .1tnirlc<Ltl.:., 1 ::f:'.1r ont été dun- n40z c1-4en,J"rt.c un c:hlorcre do C;:";;.:;c,..2e de iormào cér.';r&le: EMI9.4 EMI9.5 o?l .... et 5" ont 1...1tnU'1cat1ons qui Irar ont été &uu1i..... c1-ânu.a, blau bl en fait r4atir un* 2-4r7lan1no-1r:14a:ol1a.(2) de rra Il &1'..e tUt 1st. de f'or=1. génÀra1og a4. atzres d.'ha1c, tn or: -z:.: i1 :: aa a11: y2 or az> bgLe G14 /., 'S4.pw6wnA l.Ai nl3: wbW wY, 61.w..njYT irA.ly 3. "'" -, - d2hyd = gl-ne s 1eA un ra:! 1 c: 1l aryl and X # A r Lsa 1 V xi. t:. ::. e d 'oY .. :: ": en de $ Carre. carcti: is6 in that qc: a) in fact reincir wne K." (iasi i: r.w srs'¯.s.iSywâ.ivwdVr6r aubat1tu .. de t3., .ralt: EMI9.2 EMI9.3 where 1i, R and. 11) have the .1tnirlc <Ltl.:., 1 :: f: '. 1r were dun- n40z c1-4en, J "rt.c a c: hlorcre do C;:" ;;.:; C, . 2nd of iormào cer. '; R & le: EMI9.4 EMI9.5 o? l .... and 5 "have 1 ... 1tnU'1cat1ons which Irar were & uu1i ..... c1-ânu.a, blau bl in fact r4atir a * 2-4r7lan1no-1r: 14a: ol1a . (2) de rra Il & 1 '.. e tUt 1st. De f'or = 1. GenÀra1og a4. U ofl ;t 1c la .1Cro.tl..t1()n qui lu! ..t4 4cl'..'1fe e1-4o.au..et on tra.n:8tcU"'C. htuCll1"fl1t le produit !'1na.l do l'un. de ces cp4. nt10tu ai' un sol d'ad41tloa 4**cid** .- Procédé w1vaQ1; la h'W'.n41e.tlon 1*5 de ,ripat':1t1on de QOIIIt'pO.'. 4t tQf1l. 1aha1.t <Desc/Clms Page number 10> EMI10.1 EMI10.2 oà fl, c Z ''t*' s**'#T**' ' #tcr*± =i?-aÎ=µÎ=r#> * 7 :1:# +ioe ==41é=<#ce è$ a#c=es d, ct.lmre ;t I¯ i 1- iiç=#ifi.>."#F<T xYf, lui a àJnxÔ± ci-dessus, ft>tao#à=il.ô -= '3e ùgm e=ù lÎ=.-3 J)=fli.h une 2-c.?'.j''l'<'':.?..c-isida.sIi'!''-S pn !::1:' <'*'E.2.T. EMI10.3 EMI10.4 ûH S ; n C* <5 eP bt vw' 1' w as.,3 e¯ -Ho? A'"I')""'7 t"'' >1'- ->r:,Ci'" ',...,... U ofl; t 1c la .1Cro.tl..t1 () n who read! ..t4 4cl '..' 1fe e1-4o.au..and one tra.n: 8tcU "'C. htuCll1" fl1t the product!' 1na.l do one. of these cp4. nt10tu have a sol of ad41tloa 4 ** cid **. Method w1vaQ1; the h'W'.n41e.tlon 1 * 5 of, ripat ': 1t1on of QOIIIt'pO.'. 4t tQf1l. 1aha1.t <Desc / Clms Page number 10> EMI10.1 EMI10.2 o to fl, c Z '' t * 's **' # T ** '' # tcr * ± = i? -aÎ = µÎ = r #> * 7: 1: # + ioe == 41é = <# ce è $ a # c = es d, ct.lmre; t I¯ i 1- iiç = # ifi.>. "# F <T xYf, him to JnxÔ ± above, ft> tao # to = il.ô - = '3e ùgm e = ù lÎ = .- 3 J) = fli.h a 2-c.?'.j''l'<'':.?..c-isida.sIi'!''- S pn! :: 1: '<' * 'E.2.T. EMI10.3 EMI10.4 ûH S; n C * <5 eP bt vw '1' w as., 3 ē -Ho? A '"I')" "'7 t"' '> 1'- -> r:, Ci' "', ..., ... "'1 et :'2 on les --.....C",.¯.¯-¯y",,<4Y';;;' "j,II#'" -"'.,./ "-:-..3- ...'-.. *,- et..................,. ".. Icseyanstc de "''-4'; jliil-.=Le> -*x:=: >+ +±%µ2fi " ±1 Li s 3' a 'a....<t¯...",r".....t1""n""t ",1t 3. 3: A a, :o <-C2.'3\ Prced suivant :i:5 r*1+nài:;;.>tlc.n> 1> a éù préparatizn do c::,s's de t.:.:--:'1:'6 :"=r:1:-:.;:.t EMI10.5 EMI10.6 lof i i/ y ,f %a &tç--ez de sr J59e ù== iin **"'!l':.l ybx.Fiii;Î= j zizi l.Vf1M41.5-sk Y b9vss'b z#bJlt#=71ts â1 rs '&'3c,. :c9 :1?iiilczt r.f c..s .6aâ.sxr" ea-.tx car-cttriz4 r-e ea%ax nty, caractéris6 en <!c gu'>;> 1*=ii 7--'..,:-? 2-Tù,É àà=> chlorc-I.<''n:.'ln?)-iEid&.:o'H':?-(S3 . â9 in d=#..#ô= .>iat+ f > tJr=#1+ EMI10.7 <Desc/Clms Page number 11> EMI11.1 ""-. l ;'-i"".f.;-i,. 'si:':J' si-dessus,. v,. ' a,j, : "'1 and:' 2 we have them --..... C",. ¯.¯-¯y ",, <4Y ';;;' "j, II # '" - "'.,. /" -: - .. 3- ...'- .. *, - and ................. .,. ".. Icseyanstc de" '' -4 '; jliil -. = Le> - * x: =:> + + ±% µ2fi "± 1 Li s 3' a 'a .... <t¯ ... ", r" ..... t1 "" n "" t ", 1t 3. 3: A a,: o <-C2.'3 \ Prced following: i: 5 r * 1 + nài: ;;.> tlc.n> 1> a éù preparatizn do c ::, s's de t.:.:--:'1:'6: "= r: 1: -:.;:. t EMI10.5 EMI10.6 lof ii / y, f% a & tç - ez de sr J59e ù == iin ** "'! l':. l ybx.Fiii; Î = j zizi l.Vf1M41.5-sk Y b9vss'b z # bJlt # = 71ts â1 rs' & '3c ,.: c9: 1? iiilczt rf c..s .6aâ.sxr "ea-.tx car-cttriz4 re ea% ax nty, characterized as <! c gu'>; > 1 * = ii 7 - '..,: -? 2-Tù, É àà => chlorc-I. <'' N:. 'Ln?) - iEid & .: o'H':? - (S3. Â9 in d = # .. # ô =.> Iat + f > tJr = # 1 + EMI10.7 <Desc / Clms Page number 11> EMI11.1 "" -. l; '- i "". f.; - i ,. 'if:': J 'above ,. v ,. 'a, j,: y . ¯ ¯ .-.. ¯. " ..c. - Jt !l:!:'::";'? .> 3...:vt.,rs 'i - :,. 7-:""'::"---- ....-> 7." àT - .'"- "'-"'1ro,--.:rt!!!..!!!!J.PJt':..... ""e ,"-":":";-J Ct.'.''-?'J:5 "-:-. . ..¯y ?f5 :; ;1sie3=:: #1 'f .:';.:::: ;: :: 'L .;:²2: EMI11.2 EMI11.3 ; 1 1. ;. = , ..'2",y z ±. - j. 5 1 ±.# z# 1. çi.: : . i " = 1 . " ,.,re?3-ent<.nt des sic - -;.p ¯- 3 > ", . > ,. = .,> . ;>- g ;-z ? - .? .-. e 1, iica!xal:-:yle, al:-:=xy, l ± f iÎ ' ""J'l k 2]à"+± .= , "--# ?> : [ N Ô :' . à = É 12 'R r&disal --Ze en 211 ÎS J Ô l . i 1 - 21 r-'.ifi'..:3 =µf ?' .".:'.3 aryle prisât é%'eXαC lE- i: ?;: ':-'".-.- s. ? .:..i fl .:. x= ; .- .. l , , 1 -:t>mes é ' iilcgl ne eu l;;-.i>.: :""1:= :=;:'- l l=:#: à> : y. ¯ ¯ .- .. ¯. "..c. - Jt! l:!: '::";'? .> 3 ...: vt., Rs' i -:,. 7 -: "" ':: "---- ....-> 7." àT -. '"-"' - "'1ro, - .: rt !!! .. !!!! J.PJt': ....." "e," - ":": "; - J Ct. '.' '-?' J: 5 "-: -. . ..¯y? F5:; ; 1sie3 = :: # 1 'f.:';. ::::;: :: 'L.;: ²2: EMI11.2 EMI11.3 ; 1 1.;. =, .. '2 ", y z ±. - j. 5 1 ±. # Z # 1. çi .::. I" = 1. ",., re? 3-ent <.nt des sic - - ;. p ¯- 3>",. >,. =.,>. ;> - g; -z? -.? .-. e 1, iica! xal: -: yle, al: -: = xy, l ± f iÎ '"" J'l k 2] to "+ ±. =," - #?>: [N Ô:' . à = É 12 'R r & disal --Ze en 211 ÎS J Ô l. i 1 - 21 r - '. ifi' ..: 3 = µf? ' . ".: '. 3 aryl prized%' eXÎ ± C lE- i:?;: ': -'".-.- s. ? .: .. i fl.:. x =; .- .. l,, 1 -: t> my é 'iilcgl ne had l ;; -. i> .:: "" 1: =: =;:' - l l =: #: to>: iill-ù-:ùxt 5::bztit'sé t* ;-c'r';-nt'.: ', .:- '.1;,.,*'': 4 =.#dicfl=I sryle et A repré- f::.te 1...:1 i.E. <i ù'<..z =1-5* #.i F.. r>..fà..-,E =630 qs le"J.rs s(11.s 4 ' ;à d ài t 1 = n à " à: i Li > i j ..'.*.":r 1 :. oe >efi-tabl es . iill-ù-: ùxt 5 :: bztit'sé t *; -c'r '; - nt' .: ',.: -' .1;,., * '': 4 =. # dicfl = I sryle and A represents:. te 1 ...: 1 iE <i ù '<.. z = 1-5 * # .i F .. r> .. fà ..-, E = 630 qs le "J.rs s (11.s 4'; to d toi t 1 = n to "to: i Li> ij .. '. *.": r 1:. oe> efi-tables. 8 - Îtì± àÉ c ?>Î# l = Îà ?#' c 7ùÔààCù#±XtS suivant la t'.-v<:i'-" 7 c4.i=i.ù;J#f r .J < s '' " ,. ' J# xet e cc:)s1t1on *<*; 'PX (à * ' 1 ...71 ."*'S!.. ±'-. i-I?.%è ù .'' K.,'2"HS EMI11.4 EMI11.5 s '.<,."'''> 1,.,-.+.1""u..... ri"4'4' ''*:,?rs&nt@nt l .'2 . et "'''3'.J::-.....-......!''''-....J/Io¯..,I -+-.. ':.,.¯.'......¯,-",...¯.;:..,>.:: ..W1V déJ .itt "-îc :1:1.;.ir. =" #i# y gi¯ ¯ ya'x <"- =1.%s rdi1::;Z im:.'3 aH:oxy, ''yjflw..:"''*..y'-: x ",-9> x ;M- r1.-"-:f. 4 k ae a ?.-'3 alk\.-le en rl fli<:t ,*tt..;: ? nii< rz.ài =#1 (t:;ú1ne <r= ; t r f tiit.l:(J, g ¯ ¯. aFs^¯ra;^ ¯ ^' :aryle 'ff:t:.nt t:\1flltel1- <Desc/Clms Page number 12> EMI12.1 ''::1-:': . L-:\:.."'J-'.;''*'"'f.-''<. 8 - Îtì ± àÉ c?> Î # l = Îà? # 'C 7ùÔààCù # ± XtS following t' .- v <: i'- "7 c4.i = i.ù; J # fr .J <s '' ",. 'J # x and e cc:) s1t1on * <*; 'PX (at *' 1 ... 71. "* 'S! .. ±' -. I-I?.% È ù. '' K., '2" HS EMI11.4 EMI11.5 s'. <,. "'' '> 1,., -. +. 1" "u ..... ri" 4'4' '' *:,? rs & nt @ nt l .'2. and "'' '3'.J :: -.....-......!' '' '-.... J / Iō .., I - + - ..':. , .¯ .'...... ¯, - ", ... ¯.;: ..,>. :: ..W1V deJ .itt" -îc: 1: 1.;. Ir. = " # i # y gī ¯ ya'x <"- = 1.% s rdi1 ::; Z im:. '3 aH: oxy,' 'yjflw ..:"' '* .. y'-: x " , -9> x; M- r1 .- "-: f. 4 k ae a? .- '3 alk \ .- le in rl fli <: t, * tt ..;:? nii <rz.ài = # 1 (t:; ú1ne <r =; trf tiit.l: (J, g ¯ ¯. aFs ^ ¯ra; ^ ¯ ^ ': aryle' ff: t: .nt t: \ 1flltel1- <Desc / Clms Page number 12> EMI12.1 '' :: 1-: ':. L -: \: .. "'J -'.; '' * '"' F .- '' <. ';*.'' " -'y , " " ' . " f' ¯"-W; =,P,,0;'fij , -,=z; E -, g, ¯ f 4 = ;± ' ¯ , 'Î ' lÎ= Î 1: ./. , ''' ' ' ;"' ? lÎ Tl.àé ù '= x ôi Q-flÀ'l .% i¯ è à y . fi Q ± ; .;j ¯, ' ¯ = ' ¯ gg . ] µ = ¯,5> ±1.=; Qiz " ,=j +j s.= ± =g *'341.* H.-'t ."..3 r;;/".-i.'';î.,'.' iJ=j ..5r.±% .>q¯,=,=<.: ,]=j.z r,?,i]# 1,r "E1±, 1 .i ¯ ' ' .= li"1.-=3.i, Î31¯# , . : ? '.JT:t3 à?Él;1+Jl t, tge:àts . , .% . ; .,, . = . ; '; *.' '"-'y," "'." f '¯ "-W; =, P ,, 0;' fij, -, = z; E -, g, ¯ f 4 =; ± ' ¯, 'Î' lÎ = Î 1: ./., '' '' '; "'? lÎ Tl.àé ù '= x ôi Q-flÀ'l.% ī è to y. fi Q ±; .; j ¯, '¯ =' ¯ gg. ] µ = ¯, 5> ± 1. =; Qiz ", = j + j s. = ± = g * '341. * H .-' t." .. 3 r ;; / ".- i. ''; Î., '.' iJ = j ..5r. ±%.> q¯, =, = <.:,] = jz r,?, i] # 1, r "E1 ±, 1 .i ¯ ''. = li" 1. - = 3.i, Î31¯ #,.:? '.JT: t3 to? El; 1 + Jl t, tge: àts.,.%.;. ,,. =.; 1 .,,= ? - %..> .. < * - % -.1 ¯¯1::r3::<:j g>g.,;=;m j;,,,, ± J''*S* \\\' i, = ':- i < . i ¯, t-=- 1 s¯j <= =...j -' 1".. - :s -j.'?i s c*i> s r l e, f , %J / , " J t .; h 1 7 JàÎ , J1;' - ? . 1 ".Il j ; --- .'-.'- ,) =t. .?3.-f-"' ? - " ' " ', f 1 .> 1 " L j#p <àrt. iJ: l e oei 1 daHt'9 jt 1 .,f .i ". ±.l.Jl-1>±(à .l...f.i""'Î..? ji;.Él:1?"aα2 EMI12.2 EMI12.3 =ù ii . ; " 3.i=m' - l;1.?Ôa >xo i>.=.-oe#.3#::;:t*xt drz - *''3 *=r ## .''.-... - ###' J rl âÎ*1. 1.1 ' ] 1 ," 'i). É lÎ Àà: #Î À. ' i 1 . '--'''<;'9 àà r2.'l ùÎkYÎ# :1 chs:- .'.9 r-?f-? *,; ":-"*f'''' ?/?*'':y -sryls ,:=;*,+o '?7n**''llc':'!t ¯j, E--. t= ' -. .. ; ¯ l , 1=>=" : ix=x : ±ùa. Fy 1¯1* #" ;à st i oa;) lg a<#¯¯ aikyi< ,=-8 ii.. .hTii>:. 1<> 4*.Pxts#ii<nrn; J:i1.Jtile=.1 , 3. 1. ,, =? -% ..> .. <* -% -.1 ¯¯1 :: r3 :: <: jg> g.,; =; Mj; ,,,, ± J '' * S * \\\ 'i , = ': - i <. i ¯, t - = - 1 s¯j <= = ... j - '1 ".. -: s -j.'? i s c * i> s r l e, f,% J /," J t.; h 1 7 JàÎ, J1; ' -? . 1 ". He j; --- .'-.'-,) = t..? 3.-f-" '? - "'"', f 1.> 1 "L j # p <art. iJ: l e oei 1 daHt'9 jt 1., f .i". ± .l.Jl-1> ± (to .l ... f.i "" 'Î ..? Ji; .El: 1? "AÎ ± 2 EMI12.2 EMI12.3 = ù ii. ; "3.i = m '- l; 1.? Ôa> xo i>. = .- oe # .3 # ::;: t * xt drz - *' '3 * = r ##.''.- ... - ### 'J rl âÎ * 1. 1.1'] 1, "'i). É lÎ À: # Î À. 'i 1. '-' '' <; '9 àà r2.'l ùÎkYÎ #: 1 chs: -.'. 9 r-? F-? * ,; ": -" * f '' ''? /? * '': y -sryls,: =; *, + o '? 7n **' 'llc': '! t ¯j, E--. t = '-. ..; ¯ l, 1 => = ": ix = x: ± ùa. Fy 1¯1 * #"; at st i oa;) lg a <# ¯¯ aikyi <, = - 8 ii .. .hTii> :. 1 <> 4 * .Pxts # ii <nrn; J: i1.Jtile = .1, 3. TSM- 9 ;.i #t: ;i ..;3.;à;;;7:; J:;-:: i.Il=i#1 aià Î< ' 't'? - at.1-+ ;+ ..;.,:*=:=.,4 e.a .i<1 :-..f<", ?..a kl.eta ¯1':"! rj?3 scia Il tl f&?t-'3 ';,y;'.3:'¯--":.\ Î l' ÎÀ"ÎôÎO TSM- 9; .i #t:; i ..; 3.; to ;;; 7 :; J:; - :: i.Il = i # 1 aià Î <'' t '? - at.1- +; + ..;.,: * =: =., 4 e.a .i <1: - .. f <",? .. a kl.eta ¯1 ':"! rj? 3 scia Il tl f &? t-'3 ';, y;'. 3: '¯ - ":. \ Î l' ÎÀ" ÎôÎO
BE741948D 1969-11-19 1969-11-19 N-carbonyl imidazolines BE741948A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE741948 1969-11-19

Publications (1)

Publication Number Publication Date
BE741948A true BE741948A (en) 1970-05-04

Family

ID=3855676

Family Applications (1)

Application Number Title Priority Date Filing Date
BE741948D BE741948A (en) 1969-11-19 1969-11-19 N-carbonyl imidazolines

Country Status (1)

Country Link
BE (1) BE741948A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2073369A1 (en) * 1969-11-17 1971-10-01 Boehringer Sohn Ingelheim
EP0002939A2 (en) * 1977-12-27 1979-07-11 Eli Lilly And Company Novel carbothioamides, compositions containing them and their preparation
US4513140A (en) * 1981-10-30 1985-04-23 Mcneilab, Inc. 2-Amino-4,5-dihydro-1H-imizole-1-carboxanilides

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2073369A1 (en) * 1969-11-17 1971-10-01 Boehringer Sohn Ingelheim
EP0002939A2 (en) * 1977-12-27 1979-07-11 Eli Lilly And Company Novel carbothioamides, compositions containing them and their preparation
EP0002939A3 (en) * 1977-12-27 1979-07-25 Eli Lilly And Company Novel carbothioamides, compositions containing them, their preparation and use
FR2413372A1 (en) * 1977-12-27 1979-07-27 Lilly Co Eli 2- (AMINO SUBSTITUE) - N- (PHENYL 3-SUBSTITUE) -2-IMIDAZOLIN-1-CARBOTHIOAMIDES INSECTICIDES
US4195092A (en) * 1977-12-27 1980-03-25 Eli Lilly And Company 2-(Substituted amino)-N-(3-substituted phenyl)-2-imidazoline-1-carbothioamides
US4513140A (en) * 1981-10-30 1985-04-23 Mcneilab, Inc. 2-Amino-4,5-dihydro-1H-imizole-1-carboxanilides

Similar Documents

Publication Publication Date Title
US5618818A (en) Muscarinic agonist compounds
CH506534A (en) Aromatic ethers
DE2508045A1 (en) SUBSTITUTED N- (1-BENZYLPYRROLIDINYL-2-ALKYL) BENZAMIDES, METHOD FOR THE PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE
US2417992A (en) N, n-dialkyl morpholinium alkylsulfates
BE741948A (en) N-carbonyl imidazolines
PL109657B1 (en) Method of producing new derivatives of pyrido/1,2a/pyrimidine
BR112014018985B1 (en) method for preparing a compound
HUT61002A (en) Process for producing 2-aminopyrimdine-4-carboxamide derivatives and pharmaceutical compositions comprising such compounds
Teotino et al. Synthesis and pharmacological properties of some derivatives of p‐aminophenylethanolamine
US2245539A (en) Sulphanilamide phosphoric acid derivative and process for the manufacture thereof
DE2114884A1 (en) Basically substituted derivatives of 1 (2H) -phthalazinone
US2742481A (en) Dialkylaminoimidazoline compounds and their preparation
US3366625A (en) Triiodo amino benzyl substituted amine compounds
US3138636A (en) Anthranilic acid derivatives
US2753345A (en) Substituted mercaptobenzoic acids and methods of preparing the same
US3966779A (en) Thymol derivatives and a process for their preparation
US3900476A (en) 2(2&#39;-pyrimidylamino)quinazolines and their preparation
DE1931061A1 (en) Pyrazole compounds, processes for their preparation and their use
JP2678758B2 (en) Novel propane derivative
US2755291A (en) Certain quaternary ammonium azides
US2850497A (en) New benzoic acid alkamine esters and a process for their manufacture
CA1085845A (en) 1-hydroxyphenoxy-3-ureidoethylamino-2-propanol derivatives as carbiac stimulants
US3096373A (en) N, n&#39;-bis (di-lower-alkylamino-loweralkyl) dicarboxylic acid amides
US2907765A (en) Piperazine derivatives
US2770653A (en) Diaralkylalkylenediamine preparation